Objectives-Although polymorphic variations in genes of the RAS system have previously been associated with susceptibility to AAA, such studies have been significantly limited by small sample sizes. This study was undertaken, using the largest case series yet reported, to determine whether common genetic variants of the RAS are associated with either susceptibility or severity of AAA. Methods and Results-The frequencies of 4 common genetic variants of genes related to the renin-angiotensin system were investigated in 3 geographically distinct, but ethnically similar, case-control cohorts, resulting in comparison of 1226 AAA cases with 1723 controls. In all 3 the AGTR1 1166C allele was significantly more common in AAA patients than controls (overall adjusted OR 1. Key Words: abdominal aortic aneurysm Ⅲ angiotensinogen Ⅲ angiotensin converting enzyme Ⅲ angiotensin Ⅲ Bradykinin Ⅲ genetic association Ⅲ renin T he renin-angiotensin system (RAS) is a potent mediator of cardiovascular homeostasis. The principal effector, angiotensin II (Ang II), is most widely associated with its role in the regulation of arterial blood pressure, but has been implicated in a wide range of nonpressor related actions including vascular remodeling, fibrosis, endothelial dysfunction, oxidative stress, 1,2 and dyslipidemia. 3 Reduction of Ang II levels, by inhibition of its converting enzyme (ACE), has been shown to significantly reduce cardiovascular disease morbidity and mortality. 4 Abdominal aortic aneurysm (AAA) is a common condition, being present in approximately 4% of white men between the ages of 50 to 79 years. 5 The condition is associated with a distinct familial component, with up to 20% of patients having one or more first affected relatives. 6 Evidence of a link between the RAS and abdominal aortic degeneration has been shown in experimental animal models, with exogenous Ang II inducing abdominal aortic aneurysms in the apolipoprotein E-deficient mouse, 7 and RAS blockade reducing spontaneous aortic elastic tissue degeneration in the rat, independent of changes in blood pressure. 8 In humans, ACE inhibitors have been suggested to reduce AAA rupture, an effect not observed with other antihypertensive agents. 9 Genetic polymorphisms of the RAS have been implicated as potential susceptibility candidates in a variety of vascular disorders including coronary artery disease, myocardial infarction, and hypertension. The role of the RAS related polymorphisms has been previously investigated in AAA patients. 10 -13 Fatini and coworkers, in the largest and most recent of these studies, investigated 250 cases and reported a significant association between ACE deletion homozygotes and AAA susceptibility. 10 All of the studies to date have involved small patient cohorts without adequate independent replication.
T he renin-angiotensin system (RAS) is a potent mediator of cardiovascular homeostasis. The principal effector, angiotensin II (Ang II), is most widely associated with its role in the regulation of arterial blood pressure, but has been implicated in a wide range of nonpressor related actions including vascular remodeling, fibrosis, endothelial dysfunction, oxidative stress, 1,2 and dyslipidemia. 3 Reduction of Ang II levels, by inhibition of its converting enzyme (ACE), has been shown to significantly reduce cardiovascular disease morbidity and mortality. 4 Abdominal aortic aneurysm (AAA) is a common condition, being present in approximately 4% of white men between the ages of 50 to 79 years. 5 The condition is associated with a distinct familial component, with up to 20% of patients having one or more first affected relatives. 6 Evidence of a link between the RAS and abdominal aortic degeneration has been shown in experimental animal models, with exogenous Ang II inducing abdominal aortic aneurysms in the apolipoprotein E-deficient mouse, 7 and RAS blockade reducing spontaneous aortic elastic tissue degeneration in the rat, independent of changes in blood pressure. 8 In humans, ACE inhibitors have been suggested to reduce AAA rupture, an effect not observed with other antihypertensive agents. 9 Genetic polymorphisms of the RAS have been implicated as potential susceptibility candidates in a variety of vascular disorders including coronary artery disease, myocardial infarction, and hypertension. The role of the RAS related polymorphisms has been previously investigated in AAA patients. 10 -13 Fatini and coworkers, in the largest and most recent of these studies, investigated 250 cases and reported a significant association between ACE deletion homozygotes and AAA susceptibility. 10 All of the studies to date have involved small patient cohorts without adequate independent replication.
Recently, a combinational effect of ACE, AGT, and AGTR1 SNPs has been reported for susceptibility to diabetic nephrop-athy. 14 Such studies suggest that investigations of RAS genetic variations should include consideration of combinational/epistatic effects.
This study was undertaken to determine whether any of 4 common functional variants of genes involved with the renin-angiotensin system are associated with AAA susceptibility. The largest series published to date, comprising a total of 1226 AAA cases, was examined. The results from an initial AAA cohort of 576 cases were validated in 2 additional geographically distinct, but ethnically similar, cohorts.
Methods

Case-Control Cohorts
Three geographically distinct case control series were examined in this study, resulting in comparison of a total of 1226 AAA cases and 1723 controls. The initial cohort consisted of patients from New Zealand (NZ), 80% of whom had undergone surgical AAA repair (typically AAAs Ͼ50 mm in diameter). Patients were recruited from the Otago-Southland region of the country, the majority (Ͼ97%) being of Anglo-European ancestry as reported previously. 6, 15 The control group consisted of elderly individuals without vascular disease (AAA excluded by abdominal ultrasound) from the same geographical region. 15 Male United Kingdom (UK) cases were recruited from the Aneurysm Screening Programme, Chichester, West Sussex and compared with age-strata-matched controls from the Second Northwick Park Heart Study (NPHS-II). Each control was at least as old as each of the cases within the strata. NPHSII is a prospective study of healthy White middle-aged men recruited from 9 general practices throughout the UK. At baseline all were free of coronary heart disease (CHD) and those using blood pressure or lipid lowering medication were excluded. 16 The Australian cohort was recruited from the Health in Men Study (HIMS) involving over 12 200 participants in a population based trial of screening for AAAs in the state of Western Australia. 17 Cases were matched to controls without AAAs from the same study.
Additional cohorts with coronary artery disease (CAD) and peripheral arterial disease (PAD) 15 from the same geographical region of the New Zealand as the AAA controls groups were examined to determine the specificity of any associations with vascular disease phenotype.
The following potential demographic confounders were assessed: age, gender (New Zealand only), hypertension (a history of systolic pressure Ͼ140 mm Hg or a diastolic pressure Ͼ90 mm Hg or treatment with antihypertensive medication), dyslipidaemia (total cholesterol Ͼ6.5mmol/L or on treatment for elevated cholesterol), diabetes, smoking history, and coronary heart disease (history of angina or myocardial infarction). All subjects gave written informed consent before being recruited and the investigations conforms with the principles outlined in the Declaration of Helsinki.
Genotyping
Four common functional polymorphisms of genes related to the RAS were examined in this study. These were the (1) Angiotensin converting enzyme intron 16 287-bp insertion deletion (ACE I/D, NCBI reference SNP ID: rs4646994), (2) Angiotensinogen exon 2 T704ϾC resulting in a methionine 268 to threonine substitution (AGT M268ϾT, rs699), (3) Angiotensin II type 1a receptor 3Ј UTR A1166ϾC (AGTR1 A1166ϾC, rs5186), and (4) Bradykinin receptor exon 1 5ЈUTR 9-bp (GGTGGGGAC) insertion deletion (BDKRB2 I/D, rs5223) polymorphisms. It should be noted that the AGT M268T SNP has previously been misdesignated M235ϾT. Each cohort was 
Statistical Analysis
Genotype results were compared using 2 -analysis and univariate odds ratios calculated using recessive or dominant models as appropriate. Multiple logistic regression was used to account for demographic confounders (gender, age, history of hypertension, dyslipidemia, diabetes, or tobacco smoking) in the case-control association analysis. Separate logistic regression models were fitted to the data from each geographical location and then combined using meta-analysis (Comprehensive Meta Analysis, version 2.0, Biostat). Both univariate genotype and multivariant adjusted odds ratio meta-analysis was performed. Results are expressed as means Ϯ1 SD or medians with interquartile ranges (IQR). Odds ratios are expressed with 95% confidence intervals (95% CI). Genotypes reported in tables as number (% of population) and allele frequencies (95% CI).
Results
Population Demographics
The demographics of the 3 case control series demonstrated consistent risk association between AAA and hypertension, dyslipidemia, smoking, and other cardiovascular disease, particularly ischemic heart disease. There was no association between AAA and diabetes (Table 1A through 1C) . Aneurysm diameters ranged from a median size of 34 mm (IQR 31 to 39 mm) in the Australian group to 52 mm (38 to 59 mm) in the UK and 56 mm (46 to 66 mm) in the NZ groups. This result reflects the varied recruitment strategies of the 3 cohort studies examined, with the Australian AAAs being derived from a population screening study whereas the majority (80%) of NZ patients had much larger aneurysms and had undergone surgical repair. The UK group was a mixture of patients, with the majority being recruited from an aneurysm screening and surveillance program (typically AAAs less than 50 mm in diameter).
RAS Genetic Variations in AAA
All genotypes were in Hardy-Weinberg equilibrium, except for an under representation of BDKRB2 heterozygotes in the NZ subjects (PϽ0.001).
In the initial analysis conducted on the NZ series, significant associations were observed between both the AGT 268 T homozygotes and AGTR1 1166 C allele carriers and AAA (Table 2A) . Both of these associations remained significant when adjusted for demographic confounders (Table 3) . Validation in the UK and Australian cohorts failed to confirm the AGT 268T association but did replicate the results for AGTR1 1166 C allele observation (Table 2B and 2C) . Meta-analysis resulted in an adjusted odds ratio of 1.60 (95% CI, 1.32 to 1.93, Pϭ1.1ϫ10 Ϫ6 ) for carriers of the AGTR1 1166C allele and AAA (Table 3 and Figure 1 ). No additional effect was observed by addition of other putative risk markers such as the AGT 268T or ACE D alleles. The ACE genotype was not associated with significant risk in any of the individual cohorts, but overall the ID genotype was associated with an adjusted odds ratio of 1.31 (95% CI, 1.04 to 1.65, PϽ0.03 ). 
C. Renin-Angiotensin System Genotypes Western Australian Cohorts
Specificity of Genetic Associations With AAA
The genotype and allele frequency of the 4 polymorphisms investigated were also compared with NZ CAD and PAD patients to determine the specificity of AAA associations (supplemental Table I , available online at http://atvb.ahajournals. org). The ACE D allele was significantly more common in CAD subjects than all other groups with an adjusted odds ratio of 2.6 (95% CI 1.7 to 4.0, PϽ0.0001) versus controls.
Carriers of the AGTR1 1166C allele were not significantly more common in CAD and PAD compared with controls, however PAD patients did have significantly fewer C alleles (PϽ0.006) and C carrier genotypes (PϽ0.02) than the AAA group. CAD patients were significantly less frequent carriers of the BDKRB2 deletion allele than either controls or other vascular disease groups (PϽ0.0001).
Discussion
Abdominal aortic aneurysm is a common condition being responsible for 1.3% of all deaths in 65-to 85-yr-old white men. 18 The reported prevalence rates vary depending on factors such as the threshold aortic diameter used to define an AAA and age. If the most widely accepted value of 30 mm is applied, 1% of women and 4.2% of men between the ages of 50 to 79 years are affected in a (North American) predominantly white population. 5 In British men over the age of 65 this rate increases to 7.6%. 19 Moreover, AAA has a distinct familial component with up to 20% of patients having one or more first affected relatives. 6 Verloes et al concluded that AAAs have an autosomal dominant pattern of inheritance with up to 40% penetrance, and the identification of the genes underlying the familial risk is of clinical importance. 20 The principal observation of this study was that the identification of the common 1166C variant of the angiotensin II type 1a receptor gene showed a significant association with AAA in 3 independent, geographically distinct but ethnically similar, case-control cohorts. This strong consistent association was independent of known AAA demographic confounders, including age, gender, hypertension, dyslipidemia, and smoking. The AGTR1 1166C risk association was not seen in all forms of cardiovascular disease, with the allele not being significantly associated with either peripheral or coronary artery disease. The notion that AAA and atherosclerotic occlusive PAD are clinically distinct pathophysiological entities is well established. As has previously been reported for the MMP9 C-1562T SNP, 21 the greatest variation in AGTR1 1166C genotype was observed between AAA and peripheral arterial disease subjects. The AGT 268T allele is associated with a 10% to 20% increase in plasma AGT. 22 Such elevated AGT levels have been shown to alter renin kinetics and result in higher Ang II production. 23 Such observations may provide some mechanistic insight into the apparent AGT 268 T allele epistatic aneurysm size association observed in New Zealand AAA patients. Although this effect was not replicated in the other 2 AAA cohorts, it should be noted that the New Zealand cohort had not only the largest number of patients but that they also had significantly larger aneurysms, with a greater range of values, than either the UK or Australian cohorts. Based on these results future AAA surveillance studies should consider including AGT 268 and AGTR1 1166 analysis to determine a possible epistatic influence of these genotypes on aneurysm growth rates.
The ACE intron 16 287-bp deletion allele has been previously associated with AAA susceptibility in a 250 patient cohort. 10 Although meta-analysis of all 1226 cases in this present study did indicate greater risk for heterozygotes for this polymorphism and AAA, this was at best a weak association, and risk in deletion allele homozygotes was not higher. One explanation for this would be if ACE DD subjects developed other types of cardiovascular disease, before AAA could develop, and there is support for this in the literature 24 and from our study, where the DD genotype was associated with CAD. The OR for AAA seen here is similar to that reported by us in a meta-analysis of previously published data. 25 This study aimed to replicate the observations of the initial (New Zealand) case-control study in 2 independent cohorts. Although there were differences in the mode of case identification, ranging from a population-based screening project to a clinical case selection, and consequent variability in the disease phenotype (most notably aneurysm size), all the cases meet the accepted definition of an AAA (aortic diameter Ͼ30 mm). A limitation of this study was that the UK control population was not screened for concurrent AAA. However, both the New Zealand and Australian control groups were confirmed AAA free, and the potential underascertainment in the UK control group (conservatively estimated at 7.6% 19 ) could only result in a weakening of the true association. Although the New Zealand controls were slightly younger than their case counterparts, it is well established that individuals with aortic diameters less than 25 mm at such ages are unlikely to subsequently develop an aneurysm. 26 Because this study involved comparing genetic variation in independent population groups it is reassuring to note a high degree of concordance between allele frequencies within the 3 cases-control cohorts. The most significant polymorphism in the context of this present study, AGTR1 A1166ϾC, has a reported C allele frequency of 0.301 and 0.299 in 858 French and 395 Spanish subjects, respectively, 27 further demonstrating the stability, and therefore potential utility, of these SNPs within populations of European ethnicity.
Although the AGTR1 1166C allele has been previously associated with the development of essential hypertension 28 and increased aortic stiffness in hypertensive patients, 29 these associations appear inconsistent. 30 In this study there was no association between this SNP and hypertension, nevertheless hypertension was included in the logistic regression model and the association between AGTR1 1166C and AAA susceptibility remained independent. Previously the AGTR1 A1166ϾC SNP has been reported as nonfunctional and in putative linkage disequilibrium with a variant that alters receptor sensitivity, resulting in an increased response to angiotensin II. 31 Recently the 3Ј UTR 1166 site has in fact been shown to be functional as part of a cis-regulatory site involved with microRNA gene silencing. 32 The 1166C allele has impaired microRNA binding and a consequent impairment of translation attenuation resulting in increased receptor density. Such AGTR1 receptor alterations have a number of possible effects which may influence AAA susceptibility, including enhanced matrix metalloproteinase (MMP) production, increased ECM formation, SMC migration, oxidation of LDL, and the formation of ROS leading to activation of intracellular signaling cascades (NFkB, MAP, and JAK/ STAT). 33 Angiotensin II is key player in vascular remodeling within the intima, as reported in atheromatous disease. 34 It is possible to speculate that an exaggerated response to vascular injury, as might be seen in AGTR1 1166C, could more easily spill over from the confines of the atherosclerotic intima to the media and adventitia, which is characteristic of AAA disease.
Recent studies in coronary heart disease (CHD) susceptibility have highlighted the need for replication of genetic associations in suitably sized independent populations. 35, 36 Although large CHD cohorts are relatively common in the literature, AAA genetic association studies have been severely hampered by inadequate sample sizes. AAA is far less common than CHD, is often asymptomatic before rupture, and occurs in older patient populations, all of which combine to make the establishment of large cohorts for analysis more difficult. Nevertheless, this study demonstrates the benefits of combining case-control cohort data to obtain appropriately powered genetic association analysis.
This study strongly confirms the key role of the RAS in the risk of AAA found in smaller samples by others. 10, 12 The potential for slowing AAA disease progression with medication targeting the RAS has already been suggested by a large therapeutic study. 9 Further functional work is now needed to better understand the pathophysiology behind these findings. In addition, this study highlights the potential utility of candidate based genetic association studies and emphasizes the need for replication and validation of results in suitable independent cohorts.
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